DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/004.8559 A1 Bondy Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/004.8559 A1 Bondy Et Al US 20100048.559A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/004.8559 A1 Bondy et al. (43) Pub. Date: Feb. 25, 2010 (54) PYRIDO(3.2-D)PYRIDMIDINES USEFUL FOR Related U.S. Application Data TREATINGVIRAL INFECTIONS (60) Provisional application No. 60/871,916, filed on Dec. (75) Inventors: Steven S. Bondy, Danville, CA 26, 2006. (US); William J. Watkins, Saratoga, CA (US); Lee S. Chong, Newark, CA (US); Piet Andre Publication Classification Maurits Maria Herdewijn, (51) Int. Cl. Rotselaar/Wexemaal (BE); Steven A 6LX 3/59 (2006.01) Cesar Alfons De Jonghe, Brugge C07D 47L/04 (2006.01) (BE) A 6LX 3/5.377 (2006.01) Correspondence Address: A6IP3L/2 (2006.01) GLEAD SCIENCES INC 333 LAKESIDE DR (52) U.S. Cl. ...................... 514/234.2:544/279: 544/117; FOSTER CITY, CA 94.404 (US) 51.4/264.11 (73) Assignee: Gilead Science, Inc., Foster City, CA (US) (57) ABSTRACT (21) Appl. No.: 12/519,500 This invention provides pyrido(3,2-d)pyrimidine derivatives represented by the structural formula (I), wherein: R is (22) PCT Fled: Dec. 24, 2007 amino, R is hydrogen, and R. and Rs together provide a (86) PCT NO.: PCT/EP07/11495 specific Substitution pattern, pharmaceutical acceptable addi tion salts, Stereochemical isomeric forms, N-oxides, Solvates S371 (c)(1), and pro-drugs thereof, are useful in the treatment of hepatitis (2), (4) Date: Jun. 16, 2009 C. Patent Application Publication Feb. 25, 2010 Sheet 1 of 2 US 2010/0048.559 A1 Figure 1 O O NC. N. Cl a HN Ns C b E. N. C on-\41 HN1 Y1 HN1,N1\1 \ R2 O C ls.-ls.--( " . s1S . a . S1S a H.C. N. N HC3V N N HC3V N N R2 R2 N1 N. C 9 N1 PN. R HN S.N a HNN la Patent Application Publication Feb. 25, 2010 Sheet 2 of 2 US 2010/0048.559 A1 Figure 2 O S H3C-S HN 's C a t s Cl b - N1 S-Cl HNS 1 HN S.N 2 HNSN 2 C y R2 R2 Nan-Ns-R3 d N1 ins C J.-le s ls.- 2 US 2010/0048.559 A1 Feb. 25, 2010 PYRIDO(3.2-D)PYRIDMIDINES USEFUL FOR heteroaryl and on position 4 with monoarylamino or mono TREATINGVIRAL INFECTIONS heteroarylamino and which may further be substituted on positions 2 and/or 6, being useful as capsaicin receptor modu lators. WO 2006/069805 discloses pyrido(3,2-d)pyrimidine 0001. The present invention relates to a class of novel derivatives substituted on position 6 with aryl or heteroaryl trisubstituted pyrido(3,2-d)pyrimidine derivatives. This and on both positions 2 and 4 with monoalkylamino, mono invention also relates to pharmaceutical compositions com cycloalkylamino, monoarylamino or monoarylalkylamino, prising said trisubstituted pyrido(3,2-d)pyrimidine deriva and which may further be substituted on position 7, being tives and one or more pharmaceutically acceptable excipi useful in the treatment of a disease mediated by phosphodi ents. The present invention further relates to the use of said esterase-4 activity. WO 2006/135993 discloses 2,4,6-trisub trisubstituted pyrido(3,2-d)pyrimidine derivatives as biologi stituted pyrido(3,2-d)pyrimidine derivatives 2,4,6-trisubsti cally active ingredients for manufacturing medicaments for tuted useful in the treatment of hepatitis C. the prevention or treatment of infection by a virus of the 0004. However there is a continuous need in the art for Flaviridae family, more specifically for inhibiting replication specific and highly therapeutically active compounds for pre of hepatitis C virus. venting or treating infections due to Flaviridae and pathologic conditions associated therewith, especially hepatitis C. In BACKGROUND OF THE INVENTION particular, there is a need in the art to provide drugs which are 0002. A huge number of pyrido(3,2-d)pyrimidine deriva active against hepatitis C in a minor dose in order to replace tives is already known in the art. For instance pyrido(3,2-d) existing drugs having significant side effects and to decrease pyrimidine derivatives with various Substituents on positions treatment COStS. 2, 4 and 6 (using the standard atom numbering for the pyrido 0005 Hepatitis is an inflammation of the liver that is most (3.2-d)pyrimidine moiety) are known with biological activi often caused by infection with one of three viruses known as ties such as competitive inhibition of pteroylglutamic acid, hepatitis A, B or C. Hepatitis A virus (HAV) infection is the inhibition of thrombocyte aggregation and adhesiveness, most common cause of acute hepatitis, and usually resolves antineoplastic activity, inhibition of dihydrofolate reductase spontaneously after several weeks of acute symptoms. Hepa and thymidylate synthase, e.g. from U.S. Pat. No. 2.924,599, titis B virus (HBV) and hepatitis C virus (HCV) are the most U.S. Pat. No. 3,939,268, U.S. Pat. No. 4,460,591, U.S. Pat. common viral causes of chronic hepatitis, usually defined as No. 5,167,963 and U.S. Pat. No. 5,508,281. Pyrido(3,2-d) liver inflammation persisting for more than six months. HCV pyrimidine derivatives with various substituents on positions is the second most common cause of viral hepatitis in general 2, 4, 6 and 7 (using the standard atom numbering for the and most common cause of chronic hepatitis. The World pyrido(3.2-d)pyrimidine moiety). Some of them with biologi Health Organization estimates that worldwide 170 million cal activities, are also known e.g. from U.S. Pat. No. 5,521, people (3% of the world's population) are chronically 190, U.S. patent application publication No. 2002/0049207, infected with HCV. These chronic carriers are at risk of devel U.S. patent application publication No. 2003/0186987, U.S. oping cirrhosis and/or liver cancer. In studies with a 10 to 20 patent application publication No. 2003/0199526, U.S. year follow-up, cirrhosis developed in 20-30% of the patients, patent application publication No. 2004/0039000, U.S. 1-5% of whom may develop liver cancer during the next ten patent application publication No. 2004/0106616, U.S. Pat. years. The 15% to 45% of persons with acute hepatitis C who No. 6,713,484, U.S. Pat. No. 6,730,682 and U.S. Pat. No. do recover are not subject to long-term complications and do 6,723,726. not need treatment. Since HCV and pestiviruses belong to the 0003 U.S. Pat. No. 5,654,307 discloses pyrido(3,2-d)py same virus family and share many similarities (such as, but rimidine derivatives substituted on position 4 with monoary not limited to, organisation of the genome, analogous gene lamino or monobenzylamino, and on positions 6 and 7 with products and replication cycle), pestiviruses may be adopted Substituents each independently selected from the group con as a model virus and surrogate for HCV. For example the sisting of lower alkyl, amino, lower alkoxy, mono- or dialky Bovine Viral Diarrhea Virus (BVDV) is closely related to lamino, halogen and hydroxy. WO 01/083456 discloses hepatitis C virus (HCV) and may be used as a surrogate virus pyrido(3,2-d)pyrimidine derivatives substituted on position 4 in drug development for HCV infection. with morpholinyl and on position 2 with hydroxyphenyl or 0006 HCV is a representative and highly significant morpholinoethoxyphenyl, having PI3K and cancer inhibiting member of the Flaviviridae family, a family of positive-strand activity. U.S. Pat. No. 6,476,031 discloses substituted RNA viruses. This family includes the following genera: quinazoline derivatives, including (in reaction scheme 5) a Genus Flavivirus (type species Yellow fever virus; others series of pyrido(3,2-d)pyrimidine derivatives which are sub include West Nile virus and Dengue Fever), Genus Hepacivi stituted on position 4 with hydroxy, chloro or an aryl, het rus (type species Hepatitis C virus), and Genus Pestivirus eroaryl (including pyridyl, pyrimidyl, indolyl, benzimida (type species Bovine viral diarrhea virus (BVDV); others Zolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, include classical Swine fever or hog cholera). Contrary to benzofuranyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, other families of positive strand RNA viruses such as human imidazolyl), cycloaliphatic or cycloheteroaliphatic group immunodeficiency virus (HIV), HCV seems incapable of being optionally spaced from the pyrido(3,2-d)pyrimidine integrating into the host's genome. The primary immune ring by a linker such as NH.WO 02/22602 and WO 02/22607 response to HCV is mounted by cytotoxic T lymphocytes. disclose pyrazole and triazole compounds, including 2-(1- Unfortunately, this process fails to eradicate infection in most trifluoromethylphenyl)-4-fluorobenzopyrazolyl-pyrido(3,2- people; in fact, it may contribute to liver inflammation and, d)pyrimidine and 2-(1-tri-fluoromethylphenyl)-4-methyl ultimately, tissue necrosis. The ability of HCV to escape triazolyl-pyrido(3.2-d)pyrimidine being useful as protein immune Surveillance is the Subject of much speculation. One kinase inhibitors. WO 03/062209 discloses pyrido(3,2-d)py likely means of viral persistence relies on the presence of rimidine derivatives substituted on position 7 with aryl or closely related but heterogeneous populations of viral US 2010/0048.559 A1 Feb. 25, 2010 genomes. Further studies of these quasi-species enable clas those with genotype 1 within 48 weeks of treatment and 65% sification of several genotypes and Subtypes, which have for those with genotype 4 within 48 weeks of treatment. clinical implications. About 80% of hepatitis C patients in the United States exhibit 0007. The diagnosis of hepatitis C is rarely made during genotype 1, whereas genotype 4 is more common in the the acute phase of the disease because the majority of people Middle East and Africa.
Load more

Recommended publications
  • Current Therapies for Chronic Hepatitis C
    Southern Illinois University Edwardsville SPARK Pharmacy Faculty Research, Scholarship, and Creative Activity School of Pharmacy 1-2011 Current Therapies for Chronic Hepatitis C McKenzie C. Ferguson Southern Illinois University Edwardsville, [email protected] Follow this and additional works at: https://spark.siue.edu/pharmacy_fac Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Ferguson, McKenzie C., "Current Therapies for Chronic Hepatitis C" (2011). Pharmacy Faculty Research, Scholarship, and Creative Activity. 4. https://spark.siue.edu/pharmacy_fac/4 This Article is brought to you for free and open access by the School of Pharmacy at SPARK. It has been accepted for inclusion in Pharmacy Faculty Research, Scholarship, and Creative Activity by an authorized administrator of SPARK. For more information, please contact [email protected],[email protected]. Chronic Hepatitis C & Current Therapies 1 Review of Chronic Hepatitis C & Current Therapies Reviews of Therapeutics Pharmacotherapy McKenzie C. Ferguson, Pharm.D., BCPS From the School of Pharmacy, Southern Illinois University Edwardsville, Department of Pharmacy Practice, Edwardsville, Illinois. Address for reprint requests : Southern Illinois University Edwardsville School of Pharmacy 220 University Park Drive, Ste 1037 Edwardsville, IL 62026-2000 Email: [email protected] Keywords : hepatitis C, HCV, ribavirin, interferon, peginterferon alfa-2a, peginterferon alfa-2b, albinterferon, taribavirin, telaprevir, therapeutic efficacy, safety The author received no sources of support in the form of grants, equipment, or drugs. Chronic Hepatitis C & Current Therapies 2 ABSTRACT Hepatitis C virus affects more than 180 million people worldwide and as many as 4 million people in the United States. Given that most patients are asymptomatic until late in disease progression, diagnostic screening and evaluation of patients that display high-risk behaviors associated with acquisition of hepatitis C should be performed.
    [Show full text]
  • Taribavirin.Pdf
    Virologic Response Rates of Weight-Based Taribavirin Versus Ribavirin in Treatment-Naive Patients with Genotype 1 Chronic Hepatitis C Fred Poordad,1 Eric Lawitz,2 Mitchell L. Shiffman,3 Tarek Hassanein,4 Andrew J. Muir,5 Bruce R. Bacon,6 Jamie Heise,7 Deanine Halliman,7 Eric Chun,7 and Janet Hammond7 Ribavirin-induced hemolytic anemia can prompt dose reductions and lower sustained virologic response (SVR) rates in the treatment of patients with chronic hepatitis C. The study aimed to determine if weight-based dosing of taribavirin (TBV), an oral prodrug of ribavirin (RBV), demonstrated efficacy comparable to RBV while maintaining its previ- ously demonstrated anemia advantage with fixed dose administration. A U.S. phase 2b randomized, open-label, active-controlled, parallel-group study was conducted in 278 treatment-naive patients infected with genotype 1 who were stratified by body weight and baseline viral load. Patients were randomized 1:1:1:1 to receive TBV (20, 25, or 30 mg/kg/ day) or RBV (800-1400 mg/day) with pegylated interferon alfa-2b for 48 weeks. The SVR rates in this difficult-to-cure patient demographics (mean age, 49 years; 61% male; 30% African American or Latino; high viral load; advanced fibrosis; and mean weight, 82 kg) were 28.4%, 24.3%, 20.6%, and 21.4% in the 20, 25, and 30 mg/kg TBV groups and the RBV group, respectively. There were no statistical differences in the efficacy analyses. Ane- mia rates were significantly lower (P < 0.05) in the 20 and 25 mg/kg/day TBV treatment groups (13.4% and 15.7%, respectively) compared to RBV (32.9%).
    [Show full text]
  • Synthesis of Polycyclic Compounds with Antiviral Activity
    Synthesis of polycyclic compounds with antiviral activity Eva Torres Costa ADVERTIMENT. La consulta d’aquesta tesi queda condicionada a l’acceptació de les següents condicions d'ús: La difusió d’aquesta tesi per mitjà del servei TDX (www.tdx.cat) i a través del Dipòsit Digital de la UB (diposit.ub.edu) ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d’investigació i docència. No s’autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d’un lloc aliè al servei TDX ni al Dipòsit Digital de la UB. No s’autoritza la presentació del seu contingut en una finestra o marc aliè a TDX o al Dipòsit Digital de la UB (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora. ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR (www.tdx.cat) y a través del Repositorio Digital de la UB (diposit.ub.edu) ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR o al Repositorio Digital de la UB.
    [Show full text]
  • Multidrug Treatment with Nelfinavir and Cepharanthine Against COVID-19
    Supplemental Information Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Hirofumi Ohashi1,2,¶, Koichi Watashi1,2,3,4*, Wakana Saso1,5.6,¶, Kaho Shionoya1,2, Shoya Iwanami7, Takatsugu Hirokawa8,9,10, Tsuyoshi Shirai11, Shigehiko Kanaya12, Yusuke Ito7, Kwang Su Kim7, Kazane Nishioka1,2, Shuji Ando13, Keisuke Ejima14, Yoshiki Koizumi15, Tomohiro Tanaka16, Shin Aoki16,17, Kouji Kuramochi2, Tadaki Suzuki18, Katsumi Maenaka19, Tetsuro Matano5,6, Masamichi Muramatsu1, Masayuki Saijo13, Kazuyuki Aihara20, Shingo Iwami4,7,21,22,23, Makoto Takeda24, Jane A. McKeating25, Takaji Wakita1 1Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 2Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan, 3Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan, 4MIRAI, JST, Saitama 332-0012, Japan, 5The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, 6AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 7Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan, 8Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan, 9Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan, 10Transborder Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan, 11Faculty of Bioscience, Nagahama Institute
    [Show full text]
  • Seminar2019 Paper 6 in Cell Solid Liquid Extraction.Pdf
    Journal of Chromatography A, 1488 (2017) 10–16 Contents lists available at ScienceDirect Journal of Chromatography A jo urnal homepage: www.elsevier.com/locate/chroma Development and application of an in-cell cleanup pressurized liquid extraction with ultra-high-performance liquid chromatography-tandem mass spectrometry to detect prohibited antiviral agents sensitively in livestock and poultry feces a b b c b a Huizhen Wu , Jianmei Wang , Hua Yang , Guoqin Li , Yinhuan Zeng , Wei Xia , a,∗ b,∗ Zuguang Li , Mingrong Qian a College of Chemical Engineering, Zhejiang University of Technology, Hangzhou, 310014, China b Institute of Quality and Standard for Agro-products, Zhejiang Academy of Agricultural Sciences, MOA Key Laboratory for Pesticide Residue Detection, Hangzhou, 310021, China c Institute of Animal Husbandry and Veterinary Science, Zhejiang Academy of Agricultural Science, Hangzhou 310021, China a r a t b i c l e i n f o s t r a c t Article history: An in-cell cleanup pressurized liquid extraction was developed to analyze prohibited antiviral agents in Received 12 September 2016 livestock and poultry feces. Extraction and cleanup were integrated into one step. The extraction was per- Received in revised form ◦ formed using methanol-acetonitrile (1:1, v/v) with 0.5% glacial acetic acid at 90 C, and 0.75 g of PSA was 24 December 2016 used as the adsorbent during the extraction procedure. Under optimal conditions, the average recoveries Accepted 26 January 2017 −1 for 11 antiviral drugs were 71.5–112.5% at three spiked levels (20, 40, and 100 ␮g kg ). The detection Available online 27 January 2017 limits and detection quantitations of the analysis method for the eleven antiviral drugs were 0.6–1.4 and −1 1.4–4.7 ␮g kg , respectively.
    [Show full text]
  • Appendices: V Ervolgonderzoek Medicatieveiligheid
    APPENDICES: V ERVOLGONDERZOEK MEDICATIEVEILIGHEID Dit is een bijlage bij het rapport Vervolgonderzoek Medicatieveiligheid en is opgesteld voor het Ministerie van VWS vanuit een samenwerkingsverband tussen het Erasmus MC (Rotterdam), NIVEL (Utrecht), Radboud UMC (Nijmegen) en PHARMO (Utrecht) Januari 2017 Versie 1.0 1 Appendices Hoofstuk 2: Onderzoek naar de mate van opvolging van HARM-Wrestling aanbevelingen (2009-2014) 2 Appendix 1 Appendix 1: Technische omzetting van HARM-Wrestling aanbevelingen naar indicatoren Algemene specificaties Tabel A1a. Bepaling van medicatiegebruik. Geneesmiddel of ATC-code geneesmiddelen groep Antidepressiva N06A Laag gedoseerd ASA B01AC06, B01AC08, B01AC30, N02BA15 (dosering 100mg) of N02BA01 (dosering 80mg) Benzodiazepinen N05CF, N05CD, N05BA of N05CC Beta-blokkers C07 Bisfosfonaten M05BA, M05BB, of M05XX Calcineurine remmers L04AA05 of L04AD01 Carbamazepine N03AF01 Corticosteroiden H02AB Co-trimoxazol J01EE01 Coxibs M01AH Diabetesmedicatie A10 Digoxine C01AA05 Glibenclamide A10BB01 of A10BD02 of A10BD04 H2RA A02BA Itraconazol J02AC02 Kaliumsparende diuretica C03DA, C03DB, of C03EA Kaliumverliezende diuretica C03A, C03B, C03E, C07B, C07CB03, C09BA, C09DA, C09XA52, C03C of C09DX01 Ketoconazol J02AB02 Niet-selectieve NSAID’s N02BA01, N02BA15, N02BA11, N02BA51, N02BA65 of M01A met uitzondering van M01AH, M01AX05, M01AX12, M01AX21, M01AX24, M01AX25 en M01AX26 Laxantia A06A, A02AA02, A02AA03, A02AA04, A06AC, A06AA, of A06AG Lisdiuretica C03C Macroliden J01FA of A02BD04 VKA B01AA Opioïden N02AA met uitzondering van N02AA55, N02AA59 en N02AA79, N02AB, N02AC, N02AD, N02AG, N02AE of N07BC01 Pentamidine P01CX01 PPI’s A02BC of M01AE52 RAS-remmers C09 Sotalol C07AA07 Spironolacton C03DA01 SSRI's N06AB, N06AX21 of N06AX16 Sulonylureumderivaten A10BB, A10BD02 of A10BD04 Thiazidediuretica C03A, C03B, C03EA, C07B, C09BA, C09DA, C09XA52, C09DX01 of C07CB03 TAR B01AC04, B01AC06, B01AC08, B01AC22, B01AC30, N02BA15 (dosering 100mg) of N02BA01 (dosering 80mg) Thienopyridine derivaten B01AC04, B01AC22 of B01AC30 3 Appendix 1 Tabel A1b.
    [Show full text]
  • Surveillance of Antimicrobial Consumption in Europe 2013-2014 SURVEILLANCE REPORT
    SURVEILLANCE REPORT SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe in Europe consumption of antimicrobial Surveillance Surveillance of antimicrobial consumption in Europe 2013-2014 2012 www.ecdc.europa.eu ECDC SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe 2013–2014 This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Klaus Weist. Contributing authors Klaus Weist, Arno Muller, Ana Hoxha, Vera Vlahović-Palčevski, Christelle Elias, Dominique Monnet and Ole Heuer. Data analysis: Klaus Weist, Arno Muller and Ana Hoxha. Acknowledgements The authors would like to thank the ESAC-Net Disease Network Coordination Committee members (Marcel Bruch, Philippe Cavalié, Herman Goossens, Jenny Hellman, Susan Hopkins, Stephanie Natsch, Anna Olczak-Pienkowska, Ajay Oza, Arjana Tambić Andrasevic, Peter Zarb) and observers (Jane Robertson, Arno Muller, Mike Sharland, Theo Verheij) for providing valuable comments and scientific advice during the production of the report. All ESAC-Net participants and National Coordinators are acknowledged for providing data and valuable comments on this report. The authors also acknowledge Gaetan Guyodo, Catalin Albu and Anna Renau-Rosell for managing the data and providing technical support to the participating countries. Suggested citation: European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2013‒2014. Stockholm: ECDC; 2018. Stockholm, May 2018 ISBN 978-92-9498-187-5 ISSN 2315-0955
    [Show full text]
  • Informatics Update
    http://druggablegenome.net/ http://datascience.unm.edu/ Tudor I. Oprea with contributions from Sorin Avram, Giovanni Bocci, Cristian Bologa, Oleg Ursu, Lars Juhl Jensen, Praveen Kumar, Vishal B. Siramshetty, and Gergely Zahoranszky-Kohalmi and many others Funding: U24 CA224370, U24 TR002278, U01 CA239108 (NIH) 4/14/2020 OHDSI Community Call Albuquerque, NM, via ZOOM . There are 3 main pillars at the root of successful drug discovery programs. Informatics, Data Science and Machine Learning (“AI” according to the hype cycle) are successfully used, as follows: . Diseases: Significant improvements in EMR processing, nosology, ontology, and EMR-based ML for Dx & mechanisms . Targets: Knowledge graph methods, coupled with ML, for biological discovery, target selection & validation . Drugs: From virtual screening to vaccine design, therapeutic modalities benefit from predictive methods across the board . IDG is developing methods applicable to each of these 3 areas Diseases image credit: Julie McMurry, Melissa Haendel (OHSU). All other images credit: Nature Reviews Drug Discovery 2/5/20 revision We curated 667 human genome-derived proteins and 226 pathogen-derived biomolecules through which 1,578 US FDA- approved drugs act. This set included 1004 orally formulated drugs as well as 530 injectable drugs (approved through June 2016). Data captured in DrugCentral (link) R. Santos et al., Nature Rev. Drug Discov. 2017, 16:19-34 link 2/4/20 revision U24 DK116195: GPCRs Bryan Roth, M.D., Ph.D. (UNC) Brian Shoichet, Ph.D. (UCSF) RFA-RM-16-026 U24 DK116214: Ion (DRGC) Lily Jan, Ph.D. (UCSF) Channels Michael T. McManus, Ph.D. (UCSF) U24 DK116204: Kinases Gary L. Johnson, Ph.D.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,871,799 B2 Adonato Et Al
    USOO8871799B2 (12) United States Patent (10) Patent No.: US 8,871,799 B2 adonato et al. (45) Date of Patent: Oct. 28, 2014 (54) IMINOCHROMENE ANTI-VIRAL the action of nucleophilic reagents. 5. Interactions of COMPOUNDS 2-Iminocoumarin-3-carboxamide with anthranilic acid and its derivatives. (2000) Chemistry of Heterocyclic COmpounds, vol. 36. (75) Inventors: Shawn P. Ladonato, Seattle, WA (US); pp. 1026-1031.* Kristin Bedard, Seattle, WA (US) Banerjee, S., et al. (2008) Multi-targeted therapy of cancer by genistein, Cancer Lett 269, 226-242. (73) Assignee: Kineta, Inc., Seattle, WA (US) Barnard, D. L. (2009) Animal models for the study of influenza pathogenesis and therapy, Antiviral Res 82, Al 10-122. (*) Notice: Subject to any disclaimer, the term of this Blight, J.J. et al., (2002) Highly Permissive Cell Lines for patent is extended or adjusted under 35 Subgenomic and Genomic Hepatitis C Virus RNA Replication, J. U.S.C. 154(b) by 55 days. Virology 76:13001-13014. Dafis, S., et al. (2008) Toll-like receptor 3 has a protective role (21) Appl. No.: 13/642,823 against West Nile virus infection, JVirol 82, 10349-10358. Horsmans, Y, et al. (2005) Isatoribine, an agonist of TLR7, reduces (22) PCT Filed: Apr. 20, 2011 plasma virus concentration in chronic hepatitis C infection, Hepatol ogy 42, 724-731. (86). PCT No.: PCT/US2011/033309 Johnson, C. L., and Gale, M., Jr. (2006) CARD games between virus S371 (c)(1), and host get a new player, Trends Immunol 27, 1-4. (2), (4) Date: Oct. 22, 2012 Kato, H., et al.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • EASL - Beyond Protease Inhibitors Hep C Pipeline Filling Up
    April 04, 2011 EASL - Beyond protease inhibitors hep C pipeline filling up Amy Brown With the development of hepatitis C protease inhibitors boceprevir and telaprevir all but concluded, specialists in treating the liver disease now are looking beyond the two first-in-class drugs (see tables below). Research is focusing on a combination of molecules or even a single agent that can reduce the burden of treatment, combat a wider spectrum of virus genotypes, dodge viral resistance and succeed in more patients, particularly those who have not seen relief with existing therapies. A top priority among experts gathered at the EASL International Liver Congress is developing an interferon-free regimen, to eliminate the flu-like symptoms and other side effects common with the immunostimulant, a goal that seems tantalysingly just out of reach for patients and physicians. “The real success will probably be in five or six years when we’re able to combine different oral agents, different small molecules with different modes of action and maybe get rid of interferon,” says Antonio Craxi, professor of gastroenterology and internal medicine at the University of Palermo. Viral breakthrough For now, viral breakthrough has haunted therapies that have attempted trial arms without peginterferon-alfa and ribavirin, the antiviral that makes up the other half of the current standard of care. For example, viral breakthrough forced Vertex Pharmaceuticals to cancel an arm of its phase II trial of telaprevir and VX-222 that did not include a background standard of care therapy. The trial continues in the quadruple-therapy arm, with positive interim results presented at the conference.
    [Show full text]